Bill113th CongressFiled Apr 15, 2013Health
H.Res. 161
Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (Apr 15, 2013)
Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
What just happenedApr 19, 2013
Referred to the Subcommittee on Health.
Who’s behind it
Rep. Rogers, Harold [R-KY-5](R-KY)Sponsor
7 cosponsors4 D3 R
7cosponsors1committees4actions1related bills3subjects
- Introduced in HouseApr 15, 2013
- Apr 19, 2013Committee
Referred to the Subcommittee on Health.
- Apr 15, 2013IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
- Apr 15, 2013IntroReferralIntro-H
Introduced in House
- Apr 15, 2013IntroReferral1000
Introduced in House